Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Seth B Furgeson

TitlePrincipal Investigator
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/724-5063

    Collapse Research 
    Collapse research activities and funding
    K08HL103774     (FURGESON, SETH BERNAT)Apr 18, 2011 - Mar 31, 2017
    NIH
    The role of smooth muscle PPAR gamma in neointima formation
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Kleczko EK, Nguyen DT, Marsh KH, Bauer CD, Li AS, Monaghan MT, Berger MD, Furgeson SB, Gitomer BY, Chonchol MB, Clambey ET, Zimmerman KA, Nemenoff RA, Hopp K. Immune checkpoint activity regulates polycystic kidney disease progression. JCI Insight. 2023 06 22; 8(12). PMID: 37345660.
      View in: PubMed
    2. Lai J, Furgeson S, Bjornstad P, You Z, Tommerdahl KL, Kendrick J. Leukotriene Antagonist Use is Associated With Lower Systolic Blood Pressure in Adults. Kidney Int Rep. 2023 Feb; 8(2):373-375. PMID: 36815112.
      View in: PubMed
    3. Furgeson SB, Linas S. Chlorthalidone and Advanced Chronic Kidney Disease. Clin J Am Soc Nephrol. 2022 07; 17(7):1076-1078. PMID: 35577563.
      View in: PubMed
    4. Montford JR, Bauer C, Rahkola J, Reisz JA, Floyd D, Hopp K, Soranno DE, Klawitter J, Weiser-Evans MCM, Nemenoff R, Faubel S, Furgeson SB. 15-Lipoxygenase worsens renal fibrosis, inflammation, and metabolism in a murine model of ureteral obstruction. Am J Physiol Renal Physiol. 2022 01 01; 322(1):F105-F119. PMID: 34866403.
      View in: PubMed
    5. Beck N, Furgeson S, Chonchol M, Kendrick J. Internal Medicine Residents' Perceptions of Nephrology as a Career: A Focus Group Study. Kidney360. 2020 10 29; 1(10):1052-1059. PMID: 35368786.
      View in: PubMed
    6. Lu S, Strand KA, Mutryn MF, Tucker RM, Jolly AJ, Furgeson SB, Moulton KS, Nemenoff RA, Weiser-Evans MCM. PTEN (Phosphatase and Tensin Homolog) Protects Against Ang II (Angiotensin II)-Induced Pathological Vascular Fibrosis and Remodeling-Brief Report. Arterioscler Thromb Vasc Biol. 2020 02; 40(2):394-403. PMID: 31852223.
      View in: PubMed
    7. Montford JR, Bauer C, Dobrinskikh E, Hopp K, Levi M, Weiser-Evans M, Nemenoff R, Furgeson SB. Inhibition of 5-lipoxygenase decreases renal fibrosis and progression of chronic kidney disease. Am J Physiol Renal Physiol. 2019 04 01; 316(4):F732-F742. PMID: 30649890.
      View in: PubMed
    8. Kleczko EK, Marsh KH, Tyler LC, Furgeson SB, Bullock BL, Altmann CJ, Miyazaki M, Gitomer BY, Harris PC, Weiser-Evans MCM, Chonchol MB, Clambey ET, Nemenoff RA, Hopp K. CD8+ T cells modulate autosomal dominant polycystic kidney disease progression. Kidney Int. 2018 12; 94(6):1127-1140. PMID: 30249452.
      View in: PubMed
    9. Moulton KS, Li M, Strand K, Burgett S, McClatchey P, Tucker R, Furgeson SB, Lu S, Kirkpatrick B, Cleveland JC, Nemenoff RA, Ambardekar AV, Weiser-Evans MC. PTEN deficiency promotes pathological vascular remodeling of human coronary arteries. JCI Insight. 2018 02 22; 3(4). PMID: 29467331.
      View in: PubMed
    10. Montford JR, Lehman AMB, Bauer CD, Klawitter J, Klawitter J, Poczobutt JM, Scobey M, Weiser-Evans M, Nemenoff RA, Furgeson SB. Bone marrow-derived cPLA2a contributes to renal fibrosis progression. J Lipid Res. 2018 02; 59(2):380-390. PMID: 29229740.
      View in: PubMed
    11. Montford JR, Furgeson SB. A new CTGF target in renal?fibrosis. Kidney Int. 2017 10; 92(4):784-786. PMID: 28938948.
      View in: PubMed
    12. Ranjit S, Dobrinskikh E, Montford J, Dvornikov A, Lehman A, Orlicky DJ, Nemenoff R, Gratton E, Levi M, Furgeson S. Label-free fluorescence lifetime and second harmonic generation imaging microscopy improves quantification of experimental renal?fibrosis. Kidney Int. 2016 11; 90(5):1123-1128. PMID: 27555119.
      View in: PubMed
    13. Montford JR, Lehman AM, Scobey MS, Weiser-Evans MC, Nemenoff RA, Furgeson SB. Cytosolic phospholipase A2a increases proliferation and de-differentiation of human renal tubular epithelial cells. Prostaglandins Other Lipid Mediat. 2016 11; 126:1-8. PMID: 27554058.
      View in: PubMed
    14. Ranjit S, Dvornikov A, Levi M, Furgeson S, Gratton E. Characterizing fibrosis in UUO mice model using multiparametric analysis of phasor distribution from FLIM images. Biomed Opt Express. 2016 Sep 01; 7(9):3519-3530. PMID: 27699117.
      View in: PubMed
    15. Lehman AM, Montford JR, Horita H, Ostriker AC, Weiser-Evans MC, Nemenoff RA, Furgeson SB. Activation of the retinoid X receptor modulates angiotensin II-induced smooth muscle gene expression and inflammation in vascular smooth muscle cells. Mol Pharmacol. 2014 Nov; 86(5):570-9. PMID: 25169989.
      View in: PubMed
    16. Horita H, Furgeson SB, Ostriker A, Olszewski KA, Sullivan T, Villegas LR, Levine M, Parr JE, Cool CD, Nemenoff RA, Weiser-Evans MC. Selective inactivation of PTEN in smooth muscle cells synergizes with hypoxia to induce severe pulmonary hypertension. J Am Heart Assoc. 2013 May 31; 2(3):e000188. PMID: 23727701.
      View in: PubMed
    17. Furgeson SB, Teitelbaum I. Basically, dialysis is not good enough. Clin J Am Soc Nephrol. 2013 Feb; 8(2):177-8. PMID: 23307877.
      View in: PubMed
    18. Horita HN, Simpson PA, Ostriker A, Furgeson S, Van Putten V, Weiser-Evans MC, Nemenoff RA. Serum response factor regulates expression of phosphatase and tensin homolog through a microRNA network in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2011 Dec; 31(12):2909-19. PMID: 21940949.
      View in: PubMed
    19. Nemenoff RA, Horita H, Ostriker AC, Furgeson SB, Simpson PA, VanPutten V, Crossno J, Offermanns S, Weiser-Evans MC. SDF-1a induction in mature smooth muscle cells by inactivation of PTEN is a critical mediator of exacerbated injury-induced neointima formation. Arterioscler Thromb Vasc Biol. 2011 Jun; 31(6):1300-8. PMID: 21415388.
      View in: PubMed
    20. Furgeson SB, Linas S. Mechanisms of type I and type II pseudohypoaldosteronism. J Am Soc Nephrol. 2010 Nov; 21(11):1842-5. PMID: 20829405.
      View in: PubMed
    21. Furgeson SB, Simpson PA, Park I, Vanputten V, Horita H, Kontos CD, Nemenoff RA, Weiser-Evans MC. Inactivation of the tumour suppressor, PTEN, in smooth muscle promotes a pro-inflammatory phenotype and enhances neointima formation. Cardiovasc Res. 2010 May 01; 86(2):274-82. PMID: 20051384.
      View in: PubMed
    22. Furgeson SB, Teitelbaum I. New treatment options and protocols for peritoneal dialysis-related peritonitis. Contrib Nephrol. 2009; 163:169-176. PMID: 19494611.
      View in: PubMed
    23. Nemenoff RA, Simpson PA, Furgeson SB, Kaplan-Albuquerque N, Crossno J, Garl PJ, Cooper J, Weiser-Evans MC. Targeted deletion of PTEN in smooth muscle cells results in vascular remodeling and recruitment of progenitor cells through induction of stromal cell-derived factor-1alpha. Circ Res. 2008 May 09; 102(9):1036-45. PMID: 18340011.
      View in: PubMed
    24. Furgeson SB, Chonchol M. Beta-blockade in chronic dialysis patients. Semin Dial. 2008 Jan-Feb; 21(1):43-8. PMID: 18251957.
      View in: PubMed
    25. Gonzalez OY, Musher DM, Brar I, Furgeson S, Boktour MR, Septimus EJ, Hamill RJ, Graviss EA. Spectrum of bacille Calmette-Gu?rin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis. 2003 Jan 15; 36(2):140-8. PMID: 12522745.
      View in: PubMed
    Furgeson's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (162) concept(s)
    _
    Co-Authors Expand Description
    See all (20) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)